Zobrazeno 81 - 90
of 756
pro vyhledávání: '"Jacob P. Thyssen"'
Autor:
Jonathan I Silverberg, Sonja Ständer, Jacob P Thyssen, Brian S Kim, Carla Castro, Anthony Bewley, Laurent Misery, Andrew G Bushmakin, Joseph C Cappelleri, Erman Guler, Justine Alderfer, Melissa Watkins, Gary Chan, Daniela E Myers
Publikováno v:
British Journal of Dermatology. 188
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with itch, eczematous lesions and impaired quality of life (QoL). Although the frequency of skin pain in AD is often underestimated, it is associated with a substantial health b
Autor:
Jonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, Andrew E Pink, Stephan Weidinger, Gary Chan, Irina Lazariciu, Claire Clibborn, Erman Guler
Publikováno v:
British Journal of Dermatology. 188
Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, had a superior efficacy vs. dupilumab in head-to-head randomized trials in moderate-to-severe atopic dermatitis (AD). Data on patients who switched from dupilumab to abrocitinib hav
Autor:
Jonathan I Silverberg, Sonja Ständer, Jacob P Thyssen, Brian S Kim, Carla Castro, Anthony Bewley, Laurent Misery, Andrew G Bushmakin, Joseph C Cappelleri, Erman Guler, Justine Alderfer, Melisa Watkins, Gary Chan, Daniela E Myers
Publikováno v:
British Journal of Dermatology. 188
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itch, skin pain and impaired quality of life. Skin pain is a common and bothersome symptom of AD and increases in prevalence and intensity with worsening disease
Autor:
Andrew Blauvelt, Jonathan I Silverberg, Brian M Calimlim, Yingyi Liu, Andrew Platt, Jacob P Thyssen
Publikováno v:
British Journal of Dermatology. 188
Atopic dermatitis (AD) is a debilitating chronic inflammatory skin disease with fluctuating disease severity that requires long-term control. Patients report that complete or almost complete skin clearance is highly important as a treatment goal. Upa
Autor:
Melinda Gooderham, Vivian Y Shi, Andreas Wollenberg, Jacob P Thyssen, Tiago Torres, Esther Garcia Gil, Laia Bardolet, Chitra R Natalie, Amber R Atwater, Fangyi Zhao, Andrew Blauvelt
Publikováno v:
British Journal of Dermatology. 188
Lebrikizumab is an injectable, IgG4 monoclonal antibody that selectively binds to interleukin-13 with high affinity. Injection-site reactions (ISRs) are localized adverse events in the immediate site of administration of a drug and are common with in
Autor:
Anne-Sofie Halling, Maria Rasmussen Rinnov, Iben Frier Ruge, Trine Gerner, Nina Haarup Ravn, Mette Hjorslev Knudgaard, Simon Trautner, Nikolai Loft, Lone Skov, Simon F. Thomsen, Alexander Egeberg, Emma Guttman-Yassky, Aske L.L. Rosted, Troels Petersen, Ivone Jakasa, Sanja Kezic, Jacob P. Thyssen
Publikováno v:
Journal of allergy and clinical immunology. Mosby Inc.
Background: It is unknown whether skin biomarkers collected in infancy can predict the onset of atopic dermatitis (AD) and be used in future prevention trials to identify children at risk. Objectives: This study sought to examine whether skin biomark
Autor:
Anna Korsgaard Berg, Annemarie Cecilie Grauslund, Fiona Sørensen, Steffen Ullitz Thorsen, Jacob P. Thyssen, Claus Zachariae, Jannet Svensson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5c2780ec1596fcb43b29e66d626add0
https://doi.org/10.2139/ssrn.4352548
https://doi.org/10.2139/ssrn.4352548
Autor:
S. Mark Wilkinson, Margarida Gonçalo, Olivier Aerts, Sonia Badulici, Heinrich Dickel, Rosella Gallo, Jose L. Garcia‐Abujeta, Ana M. Giménez‐Arnau, Curt Hamman, Marcos Hervella, Marléne Isaksson, Jeanne D. Johansen, Vera Mahler, Bo Niklasson, Paolo Pigatto, Gyorgyi Ponyai, Thomas Rustemeyer, Marie L. A. Schuttelaar, Radoslaw Spiewak, Luca Stingeni, Jacob P. Thyssen, Wolfgang Uter
Publikováno v:
Contact dermatitis
Wilkinson, S M, Gonçalo, M, Aerts, O, Badulici, S, Dickel, H, Gallo, R, Garcia-Abujeta, J L, Giménez-Arnau, A M, Hamman, C, Hervella, M, Isaksson, M, Johansen, J D, Mahler, V, Niklasson, B, Pigatto, P, Ponyai, G, Rustemeyer, T, Schuttelaar, M L A, Spiewak, R, Stingeni, L, Thyssen, J P & Uter, W 2023, ' The European baseline series and recommended additions : 2023 ', Contact Dermatitis, vol. 88, no. 2, pp. 87-92 . https://doi.org/10.1111/cod.14255
Wilkinson, S M, Gonçalo, M, Aerts, O, Badulici, S, Dickel, H, Gallo, R, Garcia-Abujeta, J L, Giménez-Arnau, A M, Hamman, C, Hervella, M, Isaksson, M, Johansen, J D, Mahler, V, Niklasson, B, Pigatto, P, Ponyai, G, Rustemeyer, T, Schuttelaar, M L A, Spiewak, R, Stingeni, L, Thyssen, J P & Uter, W 2023, ' The European baseline series and recommended additions : 2023 ', Contact Dermatitis, vol. 88, no. 2, pp. 87-92 . https://doi.org/10.1111/cod.14255
The European baseline series was last updated in 2019. This article discusses the reasoning behind a further iteration of the series for 2023.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9527cb9fc9e314556eaecf4a15576ee6
https://hdl.handle.net/11391/1538673
https://hdl.handle.net/11391/1538673
Autor:
Atm Rønnstad, AS Halling, Alexander Egeberg, Miriam Kolko, Jacob P. Thyssen, PM Hansen, Steffen Heegaard
Publikováno v:
Rønnstad, A, Hansen, P M, Halling, A S, Egeberg, A, Kolko, M, Heegaard, S & Thyssen, J P 2022, ' Factors associated with ocular surface disease and severity in adults with atopic dermatitis : a nationwide survey ', Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 36, no. 4, pp. 592-601 . https://doi.org/10.1111/jdv.17832
BACKGROUND: Ocular surface diseases (OSDs), including conjunctivitis and blepharitis, are common in atopic dermatitis (AD) patients, but the magnitude and patient characteristics are unclear.OBJECTIVES: To examine the prevalence of OSDs in adults wit
Autor:
Claire Feeney, Gil Yosipovitch, Daniela E. Myers, Chia-Yu Chu, Fan Zhang, Jacob P. Thyssen, Shawn G. Kwatra, Ricardo Rojo, Carle Paul, Hernan Valdez, Marco DiBonaventura
Publikováno v:
Thyssen, J P, Yosipovitch, G, Paul, C, Kwatra, S G, Chu, C Y, DiBonaventura, M, Feeney, C, Zhang, F, Myers, D, Rojo, R & Valdez, H 2022, ' Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 3, pp. 434-443 . https://doi.org/10.1111/jdv.17813
Background: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. Objectives: We examined clinically meaningful improvements in selected patient-reported outcomes (PROs). Methods: JADE COMPARE wa